Skip to main content
HR 6033 114th Congress House

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

Official title: To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.

Introduced: September 14, 2016 Introduced by: Peters, Scott H. Democratic · California See on congress.gov
Health Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationDrug therapyInfectious and parasitic diseases
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 14, 2016
Referred to the House Committee on Energy and Commerce.
Sep 14, 2016
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 14, 2016

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Democratic 1
D
Boyle, Brendan F.
Pennsylvania · Sep 14, 2016
Rothfus, Keith
· Sep 14, 2016
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6033: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act. 114th Congress. Open America. https://openamerica.io/bill/114-HR-6033/
MLA
"H.R. 6033: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-6033/.
Bluebook (legal)
H.R. 6033, 114th Cong. (2026), https://openamerica.io/bill/114-HR-6033/.
Markdown link
[H.R. 6033: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act](https://openamerica.io/bill/114-HR-6033/)
Report a problem